NuCana

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana's ProTides in clinical development were presented. Summaries of the posters are described below. NUC-3373

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

Presented Encouraging Clinical Data for NUC-3373 and NUC-7738

NuCana Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

Aldeyra Therapeutics

Lexicon Pharmaceuticals

Find out what led to the biotech industry's biggest gains.

3 Biotech Stocks That Jumped Last Week

Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

NuCana (NCNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

NuCana Appoints Andrew Kay as Board Chairman

Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

Completed Successful $ 8 0 million Public Offering

NuCana Reports Third Quarter 2020 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

NuCana to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference.

NuCana to Present at the Jefferies Virtual London Healthcare Conference

NuCana (NCNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why NuCana (NCNA) Might Surprise This Earnings Season

Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

NuCana (NCNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

NuCana (NCNA) Surges: Stock Moves 6.3% Higher

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

NuCana Presents Three Posters at the ESMO Virtual Congress 2020

EDINBURGH, United Kingdom, Sept.  21, 2020  (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889 American Depositary Shares (“ADSs”), at a public offering price of $4.50 per ADS, which includes 2,333,333 additional ADSs issued upon the exercise in full of the underwriters’ option to purchase additional ADSs. The aggregate gross proceeds to NuCana from the offering, before deducting underwriting discounts and commissions and estimated offering expenses were $80.5 million. All of the ADSs in the offering were sold by NuCana.

NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

EDINBURGH, United Kingdom, Sept.  17, 2020  (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares (“ADSs”) at a price to the public of $4.50 per ADS, for total gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. Each ADS represents one ordinary share of NuCana. In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs in the offering will be sold by NuCana. The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions.

NuCana Announces Pricing of a Public Offering of American Depositary Shares

EDINBURGH, United Kingdom, Sept.  16, 2020  (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”). Each ADS represents one ordinary share of NuCana. In addition, NuCana expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by NuCana. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

NuCana Announces Proposed Public Offering of American Depositary Shares

EDINBURGH, United Kingdom, Aug.  19, 2020  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

NuCana Reports Second Quarter 2020 Financial Results and Provides Business Update

Should You Buy NuCana (NCNA) Ahead of Earnings?

NuCana (NCNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why NuCana (NCNA) Stock Might be a Great Pick

As of late, it has definitely been a great time to be an investor of NuCana

Will NuCana Continue to Surge Higher?

Celyad

DexCom

Hologic

Teladoc

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic

NuCana Reports First Quarter 2020 Financial Results and Provides Business Update

EDINBURGH, United Kingdom, May  18, 2020  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer (NuTide:121) on May 5, 2020. NuCana has now also re-opened the Phase I and Phase Ib clinical studies of NUC-3373 and the Phase I clinical study of NUC-7738.

NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

EDINBURGH, U.K., May  05, 2020  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has begun in certain geographies, including Australia, Canada, South Korea, Taiwan, Ukraine and the United Kingdom.  NuCana will work closely with the clinicians involved in NuTide:121 to re-open all of the clinical sites to new patient enrollment as soon as practicable.

News for NuCana Stock (NCNA)